Optimi Health Corp. launched its Ibogaine Initiative, a program to extend the company’s Health Canada-licensed GMP platform to include the manufacture and supply of ibogaine. The initiative follows the United States’ first steps toward a federal policy framework intended to accelerate research and patient access to psychedelic drug products.
Ibogaine is a naturally occurring alkaloid derived from the root bark of the Tabernanthe iboga shrub, native to Central and West Africa, studied for its potential to interrupt opioid withdrawal and craving, and for its effects on substance-use disorders, post-traumatic stress disorder, and traumatic brain injury. A 2024 Stanford-led study of U.S. Special Operations veterans, published in Nature Medicine, reported reductions in PTSD, depression, anxiety, and functional disability in a cohort following a single ibogaine treatment protocol.
Optimi is commercial-stage in Australia, where authorized physicians are actively prescribing the company’s MDMA for PTSD and its naturally derived psilocybin for treatment-resistant depression. In parallel, the company supplies pharmaceutical-grade MDMA and psilocybin to clinical trials and special access programs globally. As part of its U.S. market readiness strategy, Optimi obtained an FDA Establishment Identifier number in 2025. On April 18, 2026, President Trump signed an Executive Order directing federal agencies to accelerate research, regulatory review, and patient access pathways for psychedelic drug products, including ibogaine. FDA Commissioner Marty Makary confirmed Investigational New Drug clearance for ibogaine, enabling sponsors to advance U.S. clinical trials.
The order directs the Advanced Research Projects Agency for Health to match qualifying state-level investments in psychedelic research, beginning with a $50 million federal allocation, which may be paired with Texas’s previously authorized $50 million ibogaine research commitment. The order also extends federal Right to Try eligibility to psychedelic drug products and contemplates priority review mechanisms, such as the Commissioner’s National Priority Voucher, to potentially shorten FDA review timelines.
Dane Stevens, Chief Executive Officer and Co-Founder of Optimi Health, stated: “The ibogaine market took shape in a meaningful way over the weekend following a U.S. Executive Order, and it will require high-quality, regulated supply. With a fully GMP, Health Canada-licensed manufacturing infrastructure in place, Optimi is well positioned to support this next phase of market development.”
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.biospace.com/press-releases/optimi-health-launches-ibogaine-initiative-as-u-s-executive-order-signals-pathway-for-psychedelic-drug-products